Aurinia Pharmaceuticals Inc. (AUPH) is in Healthcare, Biotechnology, based in Canada, listed on NasdaqGM. Market cap 2.16B USD. 52-week range 10.90 to 19.25 USD. Trailing P/E 7.1. Data as of 2026-10-09.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was ...